Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease

Movement Disorders

Volumn 24, Issue 7, 2009, Pages 979-983

  Hauser, Robert A ^a   Lyons, Kelly E ^b   McClain, Terry ^a   Carter, Summer ^a   Perlmutter, David ^c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^c Perlmutter Health Center   (United States)

Author keywords

Antioxidant; Glutathione; Neuroprotection; Parkinson's disease; Treatment; UPDRS

Indexed keywords

AMANTADINE; GLUTATHIONE; LEVODOPA; PERGOLIDE; PLACEBO; PRAMIPEXOLE; ROPINIROLE; SELEGILINE; TRIHEXYPHENIDYL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSPNEA; EDEMA; ERYTHEMA; FATIGUE; GAIT DISORDER; HAIR LOSS; HOT FLUSH; HUMAN; MOUTH TREMOR; MUSCLE CRAMP; NAUSEA; ORTHOSTATIC HYPOTENSION; PAIN; PARESTHESIA; PARKINSON DISEASE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SLEEP DISORDER; SWEATING; THROAT DISEASE; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE; UPPER RESPIRATORY TRACT INFECTION; VISUAL DISORDER; VIVID DREAM;

ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; DOUBLE-BLIND METHOD; DRUG EVALUATION; FEMALE; GLUTATHIONE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; PARKINSON DISEASE; PILOT PROJECTS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 67651148277     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22401     Document Type: Article

References (21)

1. Cooper AJ, Kristal BS. Multiple roles of glutathione in the central nervous system. Biol Chem 1997;378:793-802.
2. Winterbourn CC, Metodiewa D. Reaction of superoxide with glutathione and other thiols. Methods Enzymol 1995;251:81-86.
3. Clancy RM, Levartovsky D, Leszczynska-Piziak J, Yegudin J, Abramson SB. Nitric oxide reacts with intracellular glutathione and activates the hexose monophosphate shunt in human neutrophils: evidence for S-nitrosoglutathione as a bioactive intermediary. Proc Natl Acad Sci USA 1994;91:3680-3684.
4. Damier P, Hirsch EC, Zhang P, Agid Y, Javoy-Agid F. Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience 1993;52:1-6.
5. Ehrhart J, Zeevalk GD. Cooperative interaction between ascorbate and glutathione during mitochondrial impairment in mesencephalic cultures. J Neurochem 2003;86:1487-1497.
6. Janáky R, Ogita K, Pasqualotto BA, et al. Glutathione and signal transduction in themammalian CNS. Neurochem 1999;73:889-902.
7. Perry TL, Yong VW. Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci Lett 1986;67:269-274.
8. Sian J, Dexter DT, Lees AJ, Daniel S, Jenner P, Marsden CD. Glutathione-related enzymes in brain in Parkinson's disease. Ann Neurol 1994;36:356-361.
9. Sian J, Dexter DT, Lees AJ, et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 1994;36:348-355.
10. Riederer P, Sofic E, Rausch WD, et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 1989;52:515-520.
11. Sofic E, Lange KW, Jellinger K, Riederer P. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 1992;142:128-130.
12. Dexter DT, Sian J, Rose S, et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol 1994;35:38-44.
13. Chinta SJ, Andersen JK. Reversible inhibition of mitochondrial complex I activity following chronic dopaminergic glutathione depletion in vitro: implications for Parkinson's disease. Free Radic Biol Med 2006;41:1442-1448.
14. Chinta SJ, Kumar MJ, Hsu M, et al. Inducible alterations of glutathione levels in adult dopaminergic midbrain neurons result in nigrostriatal degeneration. J Neurosci 2007;27:13997-14006.
15. Klivenyi P, Andreassen OA, Ferrante RJ, et al. Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. J Neurosci 2000;20:1-7.
16. Sriram K, Pai KS, Boyd MR, Ravindranath V. Evidence for generation of oxidative stress in brain by MPTP: in vitro and in vivo studies in mice. Brain Res 1997;749:44-52.
17. Sechi G, Deledda MG, Bua G, et al. Reduced intravenous glutathione in the treatment of early Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 1996;20:1159-1170.
18. Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA 2002;287:455-463.
19. Kannan R, Mittur A, Bao Y, Tsuruo T, Kaplowitz N. GSH transport in immortalized mouse brain endothelial cells: evidence for apical localization of a sodium-dependent GSH transporter. J Neurochem 1999;73:390-399.
20. Zlokovic BV, Mackic JB, McComb JG, Weiss MH, Kaplowitz N, Kannan R. Evidence for transcapillary transport of reduced glutathione in vascular perfused guinea-pig brain. Biochem Biophys Res Commun 1994;201:402-408.
21. Kannan R, Chakrabarti R, Tang D, Kim KJ, Kaplowitz N. GSH transport in human cerebrovascular endothelial cells and human astrocytes: evidence for luminal localization of Na+-dependent GSH transport in HCEC. Brain Res 2000;852:374-382.